Skip to main content

Table 2 Prevalence of Contraindications to Combined Hormonal Contraceptives

From: Factors associated with contraceptive use among women living with HIV in Canada: a controlled, cross-sectional study

Type of Contraindication

Controls

(n = 62)

WLWH

(n = 83)

p-value

Medical Contraindication@, n (%)

6 (10%)

14 (17%)

0.14

Current Tobacco Smoker ≥ 35y, n (%)

4(6%)

25 (30%)

0.0008

Drug Contraindication*, n (%)

0 (0%)

21 (25%)

0.0001

 ≥ 1 Contraindication to CHC, n (%)

8 (13%)

45 (54%)

0.0001

  1. Bolded characters represent statistically significant values
  2. Women living with HIV (WLWH), Combined Hormonal Contraceptive (CHC)
  3. @Medical Contraindication: Hypertension, deep vein thrombosis/pulmonary embolism, diabetes with retinopathy, neuropathy, or nephropathy, diabetes > 20 years, migraine with aura, liver tumour, heart attack/myocardial infarction, stroke, severe cirrhosis, active cancer or any history of breast cancer
  4. *Drug Contraindication: Current use of rifampicin, rifabutin, phenytoin, carbamazepine, topiramate, phenobarbital, oxcarbazepine, primidone, lamotrigine, efavirenz, darunavir, or combined use of ritonavir/lopinavir
Back to article page

Reproductive Health

ISSN: 1742-4755